

XXII Riunione Nazionale I.T.M.O.

ONCOLOGIA: EVOLUZIONE DELLE CONOSCENZE

Coordinatore: Prof. Emilio Bajetta

Monza, 1 luglio 2016

Sede:

Aula Padiglione "Faggi" Istituto di Oncologia Policlinico di Monza Via Carlo Amati, 111

PROGRAMMA PRELIMINARE





Ca. della Mammella: Terapia Medica Fase adiuvante

Serena Di Cosimo Istituto Nazionale dei Tumori Milano

Breast cancer adjuvant therapy





The New England Journal of Medicine

Copyright, 1976, by the Massachuseus Medical Society


Volume 294

FEBRUARY 19, 1976


Number 8

COMBINATION CHEMOTHERAPY AS AN ADJUVANT TREATMENT IN OPERABLE BREAST CANCER





Lesson from 30 years of research



COLONIC 34 - HOMBER 14 - MIAT 10, 2010

JOURNAL OF CLINICAL ONCOLOGY

CORRESPONDENCE

Pro

Is It Time to Redefine Prognostic and Predictive in Oncology?

To THE EDITOR: Ballman¹ recently restated the often-quoted definition of prognostic and predictive oncology biomarkers by writing, "A prognostic biomarker informs about a likely cancer outcome...independent of treatment received," and continues, "A biomarker is predictive if the treatment effect...is different for biomarker-positive patients as compared with biomarker-negative patients.^{m(p3968)} Although these terms served a past purpose, they do not work well in today's sophisticated diagnostic and treatment settings.

An examination of titles of articles published in Journal of Clinical Oncology in the last two years revealed that the word prognostic appeared 33 times and predictive appeared 10 times (Reference Manager search). This reveals the confusion engendered by these terms; examples of titles include "Prognostic Significance of Diffuse Large B-Cell Lymphoma Cell of Origin Determined by Digital Gene Expression in Formalin-Fixed Paraffin-Embedded Tissue Biopsies,"2 "Prognostic Value of Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancers From Two Phase III Randomized Adjuvant Breast Cancer Trials: ECOG 2197 and ECOG 1199,"3 and "Final Results of a Prospective Evaluation of the Predictive Value of Interim Positron Emission Tomography in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP-14 (SAKK 38/07)."* In the first two studies, prognostic could have been replaced with predictive, using the definitions noted previously. The last study used the term predictive in the title but prognostic throughout the text.

It is unlikely that the authors, reviewers, or editors were unaware of the standard definitions of prognostic versus predictive but, rather, were demonstrating a reasonable shift in their use of language. When the terms were first applied, the methodologies for interrogating the nature of a malignant tissue, extent of the disease, and means to deal with the disease were limited to local methods, such as surgery and radiation. However, over the past decades, there have been dramatic improvements in our understanding of malignant disease and its treatment. Although the concepts of prognostic and predictive markers are still relevant, it would be useful to redefine them to include the following three caveats: (1) apply to these patients; (2) receiving this therapy; and (3) at this time. Using these criteria, and in keeping with the usage in the previously cited articles, a prognostic biomarker is a characteristic/ measurement that provides information about differences in outcome of a group of patients when treated in a defined manner. A prognostic biomarker is one that is associated with the outcome but may or may not be informative as to the reason for the differential response. A predictive biomarker, in this molecular age of personalized medicine, is one the presence of which is required for the treatment to work. In contrast to the prognostic biomarker, the predictive biomarker almost completely explains response to treatment. The differences are illustrated in the following discussion.

In the myelodysplastic syndromes, patients with del(5q) receiving supportive care alone have a better outcome compared with patients with multiple chromosome abnormalities. Here, the presence of del(5q) is prognostic. Patients with del(5q) also have a greater dnance of benefitting from oral lenalidomide.⁵ Using the older terminology, del(5q) would be a predictive factor, but using the new terminology, it is a prognostic factor because only an association exists between the chromosome change and response to drug. Similarly, in the third article claiming positron emission tomography scanning to be predictive the title would be reworded to, "Final Results of a Prospective Evaluation of the Prognostic Value..." because the change in the positron emission tomography scan is associated with the outcome but does not explain it.

To reduce the ambiguity between what is a prognostic or predictive biomarker, the term predictive should be reserved for instances in which the biomarker is the target of the therapy and needs to be present for the traitment response to occur. For example, in chronic myeloid leukenia, the presence of the Bcr-abl transcript/ protein predicts a high rate of response to imatinib-mediated tyrosine kinase inhibition.⁶ Similarly, in solid tumors, the presence of mutations in *EGFR* and *BPAF* predict the response to drugs, such as gefitinib in lung cancer and venurafinib in melanoma, respectively.^{7,8}

In conclusion, a biomarker should be considered prognostic when its presence or absence is associated with a better or worse outcome in a defined group of patients treated in an identical marner, of note, the prognostic relevance of a marker can change if there is a change in the patient population or treatment. The term predictive biomarker should be reserved for instances in which the marker is the target of the therapeutic agent and must be present for the drug to work.

Mark Minden

Princess Margaret Cancer Centre, Toronto, Canada

ACKNOWLEDGMENT

Supported by the Orsino Chair in Leukemia Research.

AUTHOR'S DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

Disclosures provided by the authors are available with this article at www.jco.org.

REFERENCES

 Balman KV: Biomarker: Predictive or prognostic? J Clin Oreci 33:39683971, 2015

 ScattDW, Matok A, Ennishi D, et al: Prognostic significance of diffuse large Bool lymphoma cell of origin determined by digital gene expression in formalifixed paraffin-embedded tissue biopsies. J Clin Chod 33:2248-2856, 2015

 Adams S, Gray RJ, Demaria S, et al: Prognostic value of tumorinfiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J Gin Oncol 32:2959-2966, 2014

 Marnot C, Klingblai D, Hitz F, et al: Final results of a prospective evaluation of the predictive value of interim positron emission tomography in patients with diffuse large B-cell lymphoma treated with R-CHOP-14 (SAKK 38/07). J Clin Oncol 33:2523-2529, 2015

S yead YY, Scott LJ: Lenaidomida: A review of its use in patients with transfusion-dependent anaemia due to low-or intermediate 1-tisk mydiodysplastic syndrome associated with 5q chromosome deletion. Drugs 73:1183-1196, 2013

lent of rrence.

ors

to a given [.]apy.

Ada

-

Prognostic fac therapy, and c

Predictive fac therapeutic m

Decision making


Tumor characteristics T, N, grade, ER, PgR, HER2, LVI molecular profile

Patient characteristics

age, comorbidities, prior therapy, performance status, personal choices

Clinical trial guidelines

PROGNOSTIC SIGNIFICANCE OF 5 INTRINSIC SUBTYPES OF BREAST CANCER



Common commercially available prognostic gene signatures

	MammaPrint	Oncotype DX	Breast Cancer Index	Mapquant DX	PAM 50 ROR	EndoPredict
Provider	Agendia	Genomic Health	Biotheranostics	lpsogen	NanoString	Sividon
Type of Assay	70-gene assay	21-gene recurrence score	2-gene ratio (H/I) and molecular grade index	Genomic grade	50-gene assay	12-gene assay
Type of Sample	Fresh or frozen or FFPE	FFPE	FFPE	Fresh or frozen or FFPE	FFPE	FFPE
Technique	DNA microarray or qRT-PCR	qRT-PCR	qRT-PCR	DNA microarray or qRT-PCR	qRT-PCR	qRT-PCR
Clinical Application	Prognosis of N0, < 5 cm, stage I/II, age < 61	Prediction of recurrence risk in ER+ and N0 treated with TAM	Prognostic in ER+, prediction of response to TAM	Molecular grading for ER+, histologic grade II disease	Originally for intrinsic subtyping, recurrence prediction	Recurrence prediction for ER+ HER2–
Results Presentation	Dichotomous, good or poor prognosis	Continuous variable	Continuous variable	Dichotomous, GGI I or GGI III	Continuous variable	Dichotomous, low or high risk
Level of Evidence	II	I		III	1	I
FDA Approval	YES	NO	NO	NO	YES	NO

Abbreviations: ER+, estrogen receptor–positive; FDA, U.S. Food and Drug Administration; FFPE, formalin-fixed, paraffin-embedded; GGI, Genomic Grade Index; qRT-PCR, quantitative reverse transcription polymerase chain reaction; TAM, tamoxifen.

Oncotype Dx or RS assay for patients with ER+, LN- disease:

• 16 cancer and 5 reference genes from 3 studies:

PROLIFERATION	ESTROGEN	INVASION HER-2	OTHER	REFERENCE
- Ki-67	- ER	- Stremolysin 3 - GRB-7	- GSTM1	- Beta-actin
- STK-15	- PR	- Cathepsin L2 - HER-2	2 - BAG-1	- GAPDH
- Survivin	- BCL-2		-CD-68	- RPLPO
- Cyclin B1	- SCUBE-2			- GUS
- MYBL2				- TFRC
				F

Recurrence Score =		
+ 0.47 x HER-2 Group Score		
- 0.35 x ER-2 Group Score		
+ 1.04 x Proliferation Group Score		
+ 0.10 x Invasion Group Score		
+ 0.05 x CD-68		
-0.08 x GSTM1		
- 0.07 V BAG-1 B		

U/ X DAG-1

Category	RS 0-100
Low risk	RS <18
Intermediate risk	RS ≥18 to ≤31
High risk	RS ≥ 31

NCI Cooperative Groups TAILORx The high OS rate in node negative HR positive EBC pts

nerapy


Registry

The mean of rate in noise megative in positive would be additional benefit would be additional benefit would be write that no additional benefit would be wr achieved with chemotherapyin this cohort of patients Chemotherapy + **Hormone Rx**

Hormone Rx

Primary study group

Recurrence Score distribution by grade and by Ki-67



Utility of OncotypeDx (in the presence of a dedicated path)

It has been argued that RS can be supplanted by improvements in pathologic grading and quantitative hormone receptor scoring.


However, the PlanB study suggests that this may not be true. Even with central laboratory grading, **6 percent of high-grade tumors had a low RS** and **5 percent of low Ki67 tumors had a high RS**.

Further, the reproducibility of grade as well as measures of proliferation such as immunohistochemistry analysis of Ki67, is poor between central and local laboratories.




MINDACT TRIAL DESIGN






MINDACT population at 5y median follow-up DMFS IN ALL 4 RISK GROUPS






MINDACT population at 5y median follow-up DISCORDANT RISK GROUPS: PRIMARY TEST



Proposed future clinical use of MammaPrint®



- Mindact results provide level 1A evidence of the clinical utility of MammaPrint® for assessing the lack of a clinically relevant chemotherapy benefit in the clinically high risk (c-High) population.
- c-High/g-Low patients, including 48% Node positive, had a 5-year DMFS rate in excess of 94%, whether randomized to adjuvant CT or no CT.
- In the <u>entire MINDACT population</u>, the trial confirmed the hypothesis that the « genomic » strategy leads to a 14% reduction in CT prescription versus the « clinical » strategy.
- <u>Among the c-High risk patients</u>, the clinical use of MammaPrint® is associated with a 46% reduction in chemotherapy prescription.

Considerations for the future

Disseminated tumor cells (DTC) on BMA assessment	Prognostic in EBC Marker of recurrence
Circulating tumor cells (CTC)	Poor survival after NACT or primary breast cancer surgery
cf-DNA (cell free-DNA) Plasma miRNA	Markers of relapse in EBC



EBCTCG 2011

Compared with no treatment, the use of anthracycline-containing regimen was associated with the following outcomes at 10 years:

Risk of recurrence	Significant improvement	RR 0.73	Absolute gain of 8%
Breast cancer mortality	Significant reduction	RR 0.79	Absolute gain of 6.5%
Overall mortality	Significant reduction	RR 0.84	Absolute gain of 5%

Compared with no treatment, the use of CMF was associated with these outcomes at 10 years:

Risk of recurrence	Significant improvement	RR 0.7	Absolute gain of 10.2%
Breast cancer mortality	Significant reduction	RR 0.76	Absolute gain of 6.2%
Overall mortality	Significant reduction	RR 0.84	Absolute gain of 4.7%

Anthracycline-based therapy vs. CMF

The use of "standard" doses of anthracyclines was associated with the following outcomes at 10 years compared with CMF (n=5122 women)

No improvement in the risk of recurrence (RR 0.99)

No improvement in breast cancer mortality (RR 0.98)

No improvement in overall mortality (RR 0.97)

The use of higher cumulative doses of anthracyclines (> 4 cycles, to cumulative dose of >240 mg/m²) compared with CMF was associated with the following outcomes at 10 years (n=9572)

Reduction in risk of recurrence	RR 0.89	Absolute gain of 2.6%
Reduction in breast cancer mortality	RR 0.80	Absolute gain of 4.1%
Reduction of overall mortality	RR 0.84	Absolute gain of 3.9%

EBCTCG 2012 meta-analysis

Trials where the same control regimen was used in both arms (n=11,167 women) (8 year outcome):

Reduction in risk of recurrence	RR 0.84	Absolute gain of 4.6% in RFS
Reduction in breast cancer mortality	RR 0.86	2.8% improvement in breast cancer-specific OS
Reduction in overall mortality	RR 0.86	3.2% improvement in OS

Trials where the number of cycles in the control anthracycline regimen was doubled to mirror the addition of cycles of taxanes to anthracyclines (n=33,084) (5 year outcome):

Reduction in risk of recurrence	RR 0.86	Absolute gain of 2.9%
Reduction in breast cancer mortality	RR 0.88	Absolute improvement of 1.4%
Reduction in overall mortality	RR 0.9	Absolute improvement of 1.2%

Adjuvant treatment and survival improvement over the past 40 years

